9 results about "Anorectic" patented technology

Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and / or one or more active agents are administered to a subject in need thereof to reduce or inhibit the activity of CeA PKC-δ neurons and ovBNST PKC-δ neurons in the brain of the subject. Preferably, the disclosed methods are effective to increase or excite the activity of the brain regions downstream of CeA PKC-δ neurons and ovBNST PKC-δ neurons including medial part of CeA and ventral lateral part of BNST.

The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.

This invention relates to the field of chemical pharmaceutical technology, specifically to the application of sesquiterpenoid compounds in relieving nausea and vomiting. The sesquiterpenoid compounds of this invention are cypressin and its analogues, racemates, stereoisomers, tautomers, isotope-labeled compounds, solvates, polymorphs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof, having the following structures, wherein R1-R8 are as described in the claims and specification. These sesquiterpenoid compounds can reduce kaolin ingestion in pica rats and significantly alleviate nausea and vomiting symptoms induced by chemotherapeutic drugs such as cisplatin during tumor treatment. They can also relieve vomiting caused by gastrointestinal damage, inflammatory diseases, anorexia, etc. They can be used to prepare drugs for relieving / treating nausea and vomiting or to prepare foods that help protect the gastric mucosa.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating anorexia and weight loss, comprising a Bupleuri Radix extract. Specifically, the present invention provides a pharmaceutical composition having effects in preventing, ameliorating, or treating anorexia and weight loss, wherein a Bupleuri Radix extract increases ghrilin, which is a hormone that stimulates appetite, and decreases TPH1(I), which is a serotonin synthase. In addition, a health functional food for preventing or ameliorating anorexia and weight loss, comprising a Bupleuri Radix extract, can be developed, and the extract can be effectively used for the treatment and the development of therapeutic agents for anorexia induced by chemotherapy in the future.

The application relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine for treating infantile anorexia, a topical plaster and a preparation method. The traditional Chinese medicine is prepared by combining clove, amomum villosum, fried atractylodes, fried atractylodes rhizome, costus, zedoary, radish seed and borneol with corresponding auxiliary materials. In the prescription, clove is the monarch, which can warm yang and supplement fire and warm earth; amomum villosum, atractylodes and atractylodes rhizome are the ministers, which can invigorate the spleen and eliminate dampness, assist the monarch in warming the spleen yang and eliminating dampness and ascending clear; costus, radish seed and zedoary are the aids, which can invigorate the spleen and digest food, and can lower the stomach and eliminate stagnation; borneol is slightly bitter and cold, which can open the orifices, awaken the spirit, clear heat and relieve pain, and the dispersing and diffusing function of borneol can lead the other medicines to the heart and abdomen, and disperse the orifices, and borneol is the ministerial medicine. The combination of the medicines can achieve good effects.

Pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) antagonist / inhibitor are described for use in methods of treating, ameliorating or preventing mood disorders / affective disorders and / or chronic stress and / or anxiety disorders and / or Parkinson's disease. Furthermore, pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) agonist / activator are described for use in methods of treating, ameliorating or preventing bipolar disorder manic (ICD-10 F31), appetite disorders, preferably anorexia or bulimia. Furthermore, a method of assessing the activity of a candidate molecule suspected to be a NPBWR1 antagonist / inhibitor or agonist / activator is described.

Use of sesquiterpenoids having the structures of formula (I) and formula (П) in relieving nausea and vomiting. The sesquiterpenoids having the structures of formula (I) and formula (П) are cedrol and analogs, racemates, stereoisomers, tautomers, isotopically labeled compounds, solvates, polymorphs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof, wherein R 1 to R 8 are as described in the claims and the description. The compounds having the structures of formula (I) and formula (П) can reduce kaolin intake in pica rats, significantly alleviate the symptoms of nausea and vomiting induced by chemotherapeutic drugs such as cisplatin when used in tumor treatment, and can also relieve vomiting caused by gastrointestinal injury, inflammatory diseases, anorexia, etc. In addition, the compounds having the structures of formula (I) and formula (П) can also be used in the preparation of drugs for relieving / treating nausea and vomiting or in the preparation of foods for assisting in protecting the gastric mucosa.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine oral liquid for enlivening spleen and treating anorexia and a preparation method thereof. The traditional Chinese medicine oral liquid comprises raw material medicines, a sweetening agent, an isotonic agent and water, the raw material medicines comprise the following components in parts by weight: 2-3 parts of haws, 2-3 parts of radix puerariae and 1-2 parts of roses; the sweetening agent is honey, xylitol and maltitol. Honey is replaced with the specific sweetening agent, sweet greasy feeling caused by the honey is avoided, meanwhile, oral osmotic pressure balance is adjusted in cooperation with the isotonic agent, the taste is remarkably improved, and the acceptability of a patient is higher; meanwhile, the sweetening agent has a good stabilizing effect on flavonoid active ingredients, degradation of the active ingredients is avoided, and the prepared oral liquid is longer in storage life.